Urogen Pharma (NASDAQ:URGN) Receives Average Recommendation of "Moderate Buy" from Analysts

Key Points

• Analyst sentiment is moderately bullish: Eight of ten analysts rate Urogen Pharma a buy, with one hold and one sell. The average 12-month price target is $52.38, above the reported $43.49 share price.
• Urogen shares were trading near $43.49, up 4.2%, with a market capitalization of about $2.13 billion. In its latest quarter, revenue of $72.46 million exceeded estimates, though adjusted EPS of -$0.28 missed expectations.
• Insiders have been net sellers, selling 83,067 shares worth approximately $3.71 million over the past three months, while institutional investors own a substantial 91.29% of the company.

Urogen Pharma (NASDAQ:URGN - Get Free Report) has earned a consensus rating of "Moderate Buy" from the ten research firms that are covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating on the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $52.3750.

A number of equities analysts recently weighed in on URGN shares. Weiss Ratings restated a "sell (d-)" rating on shares of Urogen Pharma in a research report on Friday, July 17th. HC Wainwright boosted their price target on shares of Urogen Pharma from $45.00 to $75.00 and gave the stock a "buy" rating in a research note on Thursday, August 6th. UBS Group reissued a "buy" rating on shares of Urogen Pharma in a report on Thursday, July 9th. Jefferies Financial Group restated a "buy" rating and set a $56.00 price objective on shares of Urogen Pharma in a research report on Thursday, September 10th. Finally, Guggenheim lifted their target price on Urogen Pharma from $42.00 to $58.00 and gave the stock a "buy" rating in a report on Thursday, August 6th.

Urogen Pharma Trading Up 4.2%

NASDAQ:URGN opened at $43.49 on Thursday. The stock has a 50-day moving average price of $43.62 and a 200 day moving average price of $32.07. The stock has a market capitalization of $2.13 billion, a P/E ratio of -21.96 and a beta of 1.57. Urogen Pharma has a 12-month low of $15.86 and a 12-month high of $50.81.

Urogen Pharma (NASDAQ:URGN - Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($0.28) EPS for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.02). The company had revenue of $72.46 million during the quarter, compared to the consensus estimate of $63.55 million. On average, research analysts predict that Urogen Pharma will post -0.2 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Urogen Pharma news, insider Mark Schoenberg sold 60,677 shares of the firm's stock in a transaction that occurred on Thursday, August 20th. The stock was sold at an average price of $47.05, for a total transaction of $2,854,852.85. Following the completion of the transaction, the insider owned 59,086 shares in the company, valued at $2,779,996.30. This trade represents a 50.66% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, General Counsel Jason Smith sold 1,519 shares of Urogen Pharma stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $42.54, for a total value of $64,618.26. Following the completion of the sale, the general counsel directly owned 53,141 shares in the company, valued at approximately $2,260,618.14. The trade was a 2.78% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 83,067 shares of company stock valued at $3,706,954. 4.80% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Urogen Pharma

Several large investors have recently bought and sold shares of the business. Opaleye Management Inc. grew its stake in shares of Urogen Pharma by 0.7% in the 2nd quarter. Opaleye Management Inc. now owns 1,439,996 shares of the company's stock worth $52,992,000 after buying an additional 9,996 shares in the last quarter. Engineers Gate Manager LP purchased a new stake in shares of Urogen Pharma during the 2nd quarter valued at about $603,000. Squarepoint Ops LLC purchased a new stake in shares of Urogen Pharma during the 2nd quarter valued at about $431,000. Wellington Management Group LLP lifted its holdings in shares of Urogen Pharma by 15.1% in the 2nd quarter. Wellington Management Group LLP now owns 115,362 shares of the company's stock valued at $4,245,000 after acquiring an additional 15,147 shares during the last quarter. Finally, Palo Alto Investors LP bought a new position in shares of Urogen Pharma in the 2nd quarter valued at about $901,600. Institutional investors own 91.29% of the company's stock.

Urogen Pharma Company Profile

UroGen Pharma Ltd. is a biopharmaceutical company focused on developing and commercializing therapies for cancers of the urinary tract. The company uses its proprietary RTGel reverse-thermal hydrogel technology to provide sustained delivery of medicines directly to affected tissues.

UroGen's primary commercial product is JELMYTO (mitomycin), a gel-based formulation approved in the United States for the treatment of adults with low-grade upper tract urothelial cancer. The company's pipeline has also included UGN-102, an investigational formulation of mitomycin being developed for patients with low-grade, intermediate-risk non-muscle-invasive bladder cancer.

Founded in 2004, UroGen is headquartered in Princeton, New Jersey, and primarily serves the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.